Although clinical response is often variable, salmeterol is at least as effective as montelukast as add-on controller in children with asthma. However, children taking salmeterol, homozygous for the arginine-16 (Arg16) allele of ADRB2, have more frequent asthma exacerbations.We therefore investigated long term asthma control in genetically susceptible children with Arg/Arg-16 who were randomized to receive montelukast or salmeterol as add-on to inhaled steroid.
Background and aims:
Although clinical response is often variable, salmeterol is at least as effective as montelukast as add-on controller in children with asthma. However, children taking salmeterol, homozygous for the arginine-16 (Arg16) allele of ADRB2, have more frequent asthma exacerbations.We therefore investigated long term asthma control in genetically susceptible children with Arg/Arg-16 who were randomized to receive montelukast or salmeterol as add-on to inhaled steroid.
Methods: 62 asthmatic children with the Arg/Arg16 genotype were randomly assigned to receive fluticasone (as Flixotide®) plus either oral montelukast, or salmeterol (as Seretide®) with placebo montelukast. The primary end-point was school absence over one year. The study was funded by an unrestricted educational grant from MSD, UK. 
Conclusions:
In children with Arg/Arg-16 genotype, montelukast may be more effective than salmeterol as add-on controller. This contrasts with the overall population of asthmatic children where salmeterol is more effective than montelukast. There is need to explore the feasibility and cost-effectiveness of ADRB2 genotype-directed choice of controller therapies in asthmatic children.
